Ani Pharmaceuticals (ANIP) Gross Profit (2012 - 2026)

Ani Pharmaceuticals has disclosed Gross Profit across 15 years of filings, most recently posting $143.9 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $143.9 million, up 15.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $561.9 million (up 40.47% YoY), and the FY2025 annual result was $542.1 million, up 48.85% from the prior year.
• Gross Profit came in at $143.9 million for Q1 2026 at Ani Pharmaceuticals, down from $146.8 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $146.8 million in Q4 2025 to a low of $30.2 million in Q1 2022.
• The 5-year median for Gross Profit is $83.7 million (2023), against an average of $90.2 million.
• Across the five-year window, Gross Profit surged 443.84% in 2022 and climbed 1.83% in 2024, its largest moves.
• Ani Pharmaceuticals' Gross Profit stood at $57.9 million in 2022, then jumped by 35.11% to $78.2 million in 2023, then surged by 40.98% to $110.3 million in 2024, then jumped by 33.09% to $146.8 million in 2025, then retreated by 1.98% to $143.9 million in 2026.
• The last three Gross Profit figures came in at $143.9 million (Q1 2026), $146.8 million (Q4 2025), and $134.4 million (Q3 2025), per Business Quant data.